Inclusion Criteria:

- Histologically confirmed CD20+ follicular lymphoma grade 1, 2 or 3a

- Have no prior systemic treatment for lymphoma.

- Must be in need of treatment

- Bi-dimensionally measurable disease with at least one mass lesion > 2 cm that was not
previously irradiated.

- Stage II, III or IV disease.

- Must be ≥ 18 years and sign an informed consent.

- Performance status ≤ 2 on the ECOG scale.

- Adequate hematological function (unless abnormalities are related to lymphoma
infiltration of the bone marrow)

- Willing to follow pregnancy precautions

Exclusion Criteria:

- Clinical evidence of transformed lymphoma by investigator assessment or Grade 3b
follicular lymphoma.

- Patients taking corticosteroids during the last 4 weeks, unless administered at a
dose equivalent to < 10 mg/day prednisone (over these 4 weeks).

- Major surgery (excluding lymph node biopsy) within 28 days prior to signing informed
consent.

- Known Seropositive for or active viral infection with hepatitis B virus (HBV),
hepatitis C virus (HCV)or human immunodeficiency virus (HIV).

- Life expectancy < 6 months.

- Known sensitivity or allergy to murine products.

- Prior history of malignancies, other than follicular lymphoma, unless the patient has
been free of the disease for ≥ 10 years.

- Prior use of lenalidomide.

- Neuropathy > Grade 1.

- Presence or history of CNS involvement by lymphoma.

- Patients who are at a high risk for a thromboembolic event and are not willing to
take venous thromboembolic (VTE) prophylaxis.

- serum aspartate transaminase (AST/SGOT) or alanine transaminase (ALT/SGPT) > 3x upper
limit of normal (ULN), except in patients with documented liver or pancreatic
involvement by lymphoma

- total bilirubin > 2.0 mg/dl (34 µmol/L) except in cases of Gilberts Syndrome and
documented liver involvement by lymphoma

- creatinine clearance of < 30 mL/min

- Pregnant or lactating females.

- Any condition, including the presence of laboratory abnormalities, which places the
patient at unacceptable risk if he/she were to participate in the study, or which
confounds the ability to interpret data from the study.